Aetion, a company specializing in real-world evidence platforms, secured funding from investors including Sanofi, Horizon Health Services, UCB, and McKesson Ventures. Their platform is utilized by top biopharma firms, payers, and the FDA, aligning with the FDA's new framework for real-world data in regulatory approvals. The funding will enhance the platform, focusing on therapeutic area intelligence, outcomes-based contracting, and global acceptance of real-world evidence standards. CEO Carolyn Magill emphasized the growing importance of real-world evidence in healthcare, spurred by legislation like the 21st Century Cures Act. Aetion employs rapid-cycle analytics to leverage various data formats for evidence generation.
Read More
Read More